[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemia-lymphoblastic-acute-pediatric\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemia-lymphoblastic-acute-pediatric":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100582301","a-swiss-assessment-of-hypothalamic-pituitary-adrenal-axis-suppression-after-glucocorticoid-therapy-for-leukemia-and-lymphoblastic-lymphoma-in-children-100582301",false,"NCT06861530","A Swiss Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children","A Swiss Prospective Multicenter Longitudinal Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children: An Explorative Study","LeukemiaCort","Inclusion Criteria:\n\n* diagnosed with ALL or LBL\n* treated for at least 21 sequential days with glucocorticoids between the 01.07.2024 and the 30.06.2027 at the Childrens University Hospital of Basel or at the Childrens Hospital of Aarau\n* lnformed consent can be obtained from the patient\\'s legal representatives (and the patient if at least 14 years of age) within week 2 of treatment with glucocorticoids\n\nExclusion Criteria:\n\n\\- Contraindication to the administration of intravenous synthetical ACTH (Synacthen®): extremely rare cases of known or suspected hypersensitivity to Synacthen®.","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","Plain Language Summary:\n\nBackground Glucocorticoids are stress hormones produced by the human body to control inflammation and regulate the immune system. Cortisol is the most well-known example of a glucocorticoid. These stress hormones are essential for the bodys healthy functioning.\n\nTo treat certain types of cancer, such as leukemia (blood cancer) in children, glucocorticoids are administered as medications in large quantities. This helps rapidly reduce the number of cancer cells in the body but also leads to the suppression of the body's natural glucocorticoid production, causing a deficiency.\n\nThis deficiency can be particularly dangerous for children with leukemia, as their immune defenses are already weakened by chemotherapy, leading to an increased risk of infections. Moreover, the signs of glucocorticoid deficiency in children with leukemia are often indistinguishable from the side effects of chemotherapy, making the deficiency harder to detect.\n\nObjectives The aim of the study is to understand how frequently and for how long the body's natural glucocorticoid production is impaired in children treated for lymphoblastic leukemia and lymphoblastic lymphoma. Additionally, the goal is to identify which children are at particularly high risk.\n\nBy gaining a better understanding, this study may help to improve the detection and treatment of glucocorticoid deficiency in children with blood cancer.\n\nMethods Regular low-dose ACTH tests will be conducted to assess the bodys natural glucocorticoid production during and after treatment. To avoid placing additional burden on children who are already heavily affected by the disease, these tests will only be performed when there is already a venous access established and the children are in the hospital for treatment reasons.",[25,26,27],"Adrenal Insufficiency","Leukemia, Lymphoblastic, Acute, Pediatric","Lymphoma, Lymphoblastic",[29,30,31,32,33,34,35],"Adrenal insufficiency","leukemia","leukaemia","childhood","pediatric","paediatric","glucocorticoid","RECRUITING","2026-05-04",{"date":39,"type":40},"2026-05-08","ACTUAL",{"date":42,"type":40},"2024-08-13",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"University Children's Hospital Basel","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100565982","childhood-b-acute-lymphoblastic-leukaemia-and-role-of-cd9-gene-regulation-in-relapse-100565982","NCT06649253","Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse","REALL CD9 : Molecular Mechanisms Involved in Relapses of Childhood B-acute Lymphoblastic Leukaemia, Role of Non-coding RNA in CD9 Gene Regulation","REALL CD9","Inclusion Criteria:\n\n* Under 18 years\n* With established diagnosis of B-ALL\n* Initial diagnosis made in the investigating centre\n* Having received oral and written information about the protocol, or oral only if the patient is unable to read.\n* Having signed a consent form if the patient is capable of giving informed written consent.\n* Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent.\n* Beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Isolated extramedullary involvement at inclusion\n* Patient of childbearing age without effective contraception.\n* Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.","0 Years","17 Years",{"count":59,"type":21},50,"INTERVENTIONAL",[62],"NA","B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.",[26],[66,67,68],"CD9","miRNA","gene regulation","2025-12-31",{"date":71,"type":40},"2026-01-02",{"date":73,"type":40},"2025-03-22",{"date":75,"type":21},"2035-04",{"name":77,"class":47},"Rennes University Hospital",3]